Arch Biopartners Inc. (TSXV:ARCH)
Canada · Delayed Price · Currency is CAD 1.240
-0.020 (-1.59%)
At close: Dec 19, 2025
Arch Biopartners Revenue
Arch Biopartners had revenue of 158.08K CAD in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to -84.71K. In the fiscal year ending September 30, 2024, Arch Biopartners had annual revenue of 2.12M with 6.97% growth.
Revenue (ttm)
-84.71K
Revenue Growth
+6.97%
P/S Ratio
-964.95
Revenue / Employee
n/a
Employees
n/a
Market Cap
81.74M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 2.12M | 138.21K | 6.97% |
| Sep 30, 2023 | 1.98M | 1.02M | 105.63% |
| Sep 30, 2022 | 964.68K | -2.92M | -75.18% |
| Sep 30, 2021 | 3.89M | 3.82M | 5,625.22% |
| Sep 30, 2020 | 67.89K | -25.99K | -27.69% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Curaleaf Holdings | 1.78B |
| dentalcorp Holdings | 1.66B |
| Trulieve Cannabis | 1.66B |
| Green Thumb Industries | 1.61B |
| Extendicare | 1.59B |
| WELL Health Technologies | 1.25B |
| Sienna Senior Living | 967.05M |
| Canopy Growth | 278.61M |
Arch Biopartners News
- 5 days ago - Arch Biopartners Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide - GlobeNewsWire
- 4 weeks ago - Arch Biopartners Closes Non-Brokered Private Placement - GlobeNewsWire
- 5 weeks ago - Arch biopartners launches non-brokered private placement - Seeking Alpha
- 5 weeks ago - Arch Biopartners Arranges Non-Brokered Private Placement - GlobeNewsWire
- 3 months ago - Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD) - GlobeNewsWire
- 4 months ago - Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury - GlobeNewsWire
- 5 months ago - Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI) - GlobeNewsWire
- 8 months ago - Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) - GlobeNewsWire